Overview

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2021-10-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the tolerability and safety of subcutaneous (SC) delivery of co-formulated daratumumab and rHuPH20 preparation (DARA SC) in Japanese participants with relapsed or refractory multiple myeloma (MM).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Antibodies, Monoclonal
Daratumumab